Sun Pharmaceutical Industries Limited — Important, 10-03-2025: General Updates

Sun Pharmaceutical Industries Limited has announced a board meeting to discuss its acquisition of Checkpoint Therapeutics, a commercial-stage immunotherapy company known for its FDA-approved UNLOXCYT™ treatment for metastatic cutaneous squamous cell carcinoma (cSCC). The acquisition includes an upfront cash payment of approximately $355 million, equating to $4.10 per share, which is about a 66% premium to Checkpoint's latest share price. Additionally, Checkpoint shareholders will receive a contingent value right worth up to $0.70 per share, contingent on future regulatory approvals.

This strategic move aims to expand Sun Pharma's global franchise in onco-dermatology and enhance patient access to innovative cancer treatments. The acquisition, requiring the approval of Checkpoint stockholders and other customary closing conditions, is anticipated to conclude by the second quarter of 2025. Given the high unmet need in treating cSCC, this acquisition represents a potential growth opportunity for Sun Pharma as it strengthens its specialty product offerings in the oncology sector.